Trial reportNature medicine2021
Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.
Open access · greenAbstract readClinical Trial, Phase IIMulticenter Study
In one paragraph
Trial report in Nature medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 1 pooled it
7.2field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 1 synthesis or guideline pooled it, 90 citations in OpenAlex.
- Pooled it
- Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study.Lancet (London, England) · 2025Trial
- Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: a phase 2 trial.Nature medicine · 2025Trial
- Dynamic genetic and nongenetic RAS-pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy.Blood · 2026Article
- C-MET tyrosine kinase receptor: mechanisms, clinical applications and future perspectives in cancer therapy.Signal transduction and targeted therapy · 2026Review
- Selumetinib in the treatment of plexiform neurofibromas in neurofibromatosis type 1: a 6-year prospective case series with review of the literature.BMC pediatrics · 2026Review
- Proteomic approaches for interrogating kinase signaling networks.The Journal of investigative dermatology · 2026Article
- MEK inhibitors for neurofibromatosis type 1-associated central and peripheral nervous system tumors.Neuro-oncology advances · 2026Review
- Neurofibromatosis type 1-plexiform neurofibromas: Integrating treatment across pediatric and adult populations.Neuro-oncology · 2026Review
- Targeted and Personalized Therapy for Difficult Benign Brain Tumors: A Review.Journal of personalized medicine · 2026Review
- Diagnosis, treatment management, and challenges in neurofibromatosis type 1: a case report with mixed features.Annals of medicine and surgery (2012) · 2026Article
- Case Report: A somaticFrontiers in neuroscience · 2026Article
- Neurofibromatosis Type 1 and the Search for Effective Tumor Therapies Using High-Throughput Drug Screening.Current oncology (Toronto, Ont.) · 2025Review
- Artificial intelligence-based tools for precision diagnosis and treatment of neurofibromatosis type 1 associated peripheral and central glial tumors.Orphanet journal of rare diseases · 2025Review
- Selective inhibition of BRAF and CRAF sensitizes NF1-deficient malignant peripheral nerve sheath tumors to MEK inhibitors.Molecular medicine (Cambridge, Mass.) · 2025Article
- Selumetinib in Adult Neurofibromatosis 1 with Plexiform Neurofibroma.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Unraveling novel variants in the NF1 gene and investigating potential therapeutic strategies.Scientific reports · 2025Article
- TGFβ-dependent signaling drives tumor growth and aberrant extracellular matrix dynamics in NF1-associated plexiform neurofibroma.Science advances · 2025Article
- Precision Medicine for Pediatric Glioma and NF1-Associated Tumors: The Role of Small Molecule Inhibitors.Current oncology (Toronto, Ont.) · 2025Review
- Treatment of Plexiform Neurofibromas : Current Perspectives on Surgery and Medical Treatment.Journal of Korean Neurosurgical Society · 2025Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 16 institutions in 1 country.
Michael J Fisher *Division of Oncology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0003-3408-3839
Chie-Schin Shih *Division of Hematology/Oncology, Department of Pediatrics, Indiana University School of Medicine, Riley Hospital for Children at Indiana University Health, Indianapolis, IN, USA.
Steven D RhodesDivision of Hematology/Oncology, Department of Pediatrics, Indiana University School of Medicine, Riley Hospital for Children at Indiana University Health, Indianapolis, IN, USA.
Amy E ArmstrongDivision of Hematology/Oncology, Department of Pediatrics, Indiana University School of Medicine, Riley Hospital for Children at Indiana University Health, Indianapolis, IN, USA.
Pamela L WoltersPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
Eva DombiPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
Chi ZhangDepartment of Medical and Molecular Genomics, Indiana University, Indianapolis, IN, USA.
Steven P AngusDivision of Hematology/Oncology, Department of Pediatrics, Indiana University School of Medicine, Riley Hospital for Children at Indiana University Health, Indianapolis, IN, USA.
Gary L JohnsonDepartment of Pharmacology, University of North Carolina-Chapel Hill, Chapel Hill, NC, USA.
Roger J PackerCenter for Neuroscience and Behavioral Medicine, Children's National Medical Center, Washington, DC, USA.
Jeffrey C AllenDepartment of Pediatrics, New York University School of Medicine, New York, NY, USA.
Nicole J UllrichDepartment of Neurology, Dana Farber/Boston Children's Hospital, Boston, MA, USA.
Stewart GoldmanDivision of Hematology/Oncology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA.
David H GutmannDepartment of Neurology, Washington University School of Medicine, St. Louis, MO, USA.
Scott R PlotkinDepartment of Neurology and Neuro-Oncology, Massachusetts General Hospital, Boston, MA, USA.
Tena RosserDivision of Neurology, Children's Hospital of Los Angeles, Los Angeles, CA, USA.
Kent A RobertsonDivision of Hematology/Oncology, Department of Pediatrics, Indiana University School of Medicine, Riley Hospital for Children at Indiana University Health, Indianapolis, IN, USA.
Brigitte C WidemannPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
Abbi E SmithDepartment of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA.
Waylan K BesslerDepartment of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA.
Yongzheng HeDepartment of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA.
Su-Jung ParkDepartment of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA.
Julie A MundDepartment of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA.
Li JiangDepartment of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA.
Khadijeh Bijangi-VishehsaraeiDivision of Hematology/Oncology, Department of Pediatrics, Indiana University School of Medicine, Riley Hospital for Children at Indiana University Health, Indianapolis, IN, USA.
Coretta Thomas RobinsonDepartment of Biostatistics, University of Alabama Birmingham, Birmingham, AL, USA.
Gary R CutterDepartment of Biostatistics, University of Alabama Birmingham, Birmingham, AL, USA.
Bruce R KorfDepartment of Genetics, University of Alabama Birmingham, Birmingham, AL, USA.
Neurofibromatosis Clinical Trials Consortium
Jaishri O BlakeleyDepartment of Neurology, Johns Hopkins University, Baltimore, MD, USA. jblakel3@jhmi.edu.
D Wade ClappDivision of Hematology/Oncology, Department of Pediatrics, Indiana University School of Medicine, Riley Hospital for Children at Indiana University Health, Indianapolis, IN, USA. dclapp@iu.edu.
Indiana University Health · USIndiana University School of MedicineNational Cancer Institute · USUniversity of Alabama at Birmingham · USUniversity of North Carolina at Chapel Hill · USBoston Children's Hospital · USChildren's Hospital of Los Angeles · USChildren's Hospital of Philadelphia · USChildren's National · USIndiana University – Purdue University Indianapolis · USJohns Hopkins University · USLurie Children's Hospital · USMassachusetts General Hospital · USNew York University · USRiley Hospital for Children · USWashington University in St. Louis · US
Funding
Pediatric Scientist Development Program (PSDP) [K12]K12HD000850 · NICHD · YALE UNIVERSITY · PI Sallie R. Permar · 1987 to 2026
$44.1MProject 4: Secondary Cancers Among NF1 Cancer SurvivorsU54CA196519 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI Yunlong Liu · 2015 to 2026
$26.9MTherapies for patients with rare tumors and genetic tumor predispositionZIASC010354 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI WIDEMANN, BRIGITTE · 2009 to 2025
$19.2MNCI NIH HHS U54 CA196519NICHD NIH HHS K12 HD000850US Army Medical Research and Development Command W81XWH-12-01-0155U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) K12-HD000850U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) U54-CA196519-04
Abstract
Neurofibromatosis type 1 (NF1) plexiform neurofibromas (PNs) are progressive, multicellular neoplasms that cause morbidity and may transform to sarcoma. Treatment of Nf1
Indexed as
AdolescentAdultAnilidesAnimalsDisease Models, AnimalFemaleGenes, Neurofibromatosis 1HumansMaleMiceMice, Mutant StrainsNeurofibroma, PlexiformNeurofibromatosis 1Pain MeasurementProspective StudiesProtein Kinase InhibitorsAnilidescabozantinibProtein Kinase InhibitorsPyridinesReceptor Protein-Tyrosine Kinases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.